Functional role of gap junctions in early and delayed cardioprotection induced by nitric oxide donors and rapid cardiac pacing by HASH(0x7fe9901e75b0)
 Functional role of gap junctions in early and delayed 
cardioprotection induced by nitric oxide donors and rapid 
cardiac pacing 
 
 
 
PhD Thesis 
 
Márton Gönczi 
 
 
 
 
 
Supervisor: Prof. Dr. Ágnes Végh 
 
 
Department of Pharmacology and Pharmacotherapy 
Albert Szent-Györgyi Medical Center 
University of Szeged, Hungary 
2013 
 
 2 
LIST OF PUBLICATIONS 
 
Full Papers 
1. Gönczi M, Papp R, Kovács M, Seprényi Gy, Végh Á. Modulation of gap junctions by 
nitric oxide contributes to the antiarrhythmic effect of sodium nitroprusside? Br J 
Pharmacol 2009; 156:786-93. IF:5.204 
 
2. Gönczi M, Kovács M, Seprényi Gy, Végh Á. The involvement of gap junctions in the 
delayed phase of protection induced by cardiac pacing in dogs. Clin Sci 2012; 123:39-51. 
IF: 4.613 
 
Full Papers not related to the thesis 
1. Papp R., Gönczi M., Kovács M., Seprényi Gy., Végh Á. Gap junctional uncoupling plays a 
trigger role in the antiarrhythmic effect of ischaemic preconditioning. Cardiovasc Res, 
2007; 74: 396-405. IF:5.820 
 
2. Papp R., Gönczi M., Végh Á A réskapcsolatok szerepe akut miokardiális iszkémia okozta 
aritmiákban Cardiologia Hungarica 2008; 38: 109-115. 
 
Abstracts for oral presentation 
 
1. Gönczi M, Papp R, Seprényi Gy, Végh Á. A réskapcsolatok szerepe a nitrogén-monoxid 
antiaritmiás hatásában. Magyar Kardiológus Társaság Kongresszusa, Balatonfüred, 2008. 
Cardiologia Hungarica 2008; 38: B15. 
 
2. Gönczi M, Papp R, Seprényi Gy, Végh Á. Role of nitric oxide in the modulation of gap 
junction channels. XXVIII. European Section Meeting of the International Society for 
Heart Research (ISHR), Athens J Mol Cell Cardiol 2008; 44: 752. 
 
3. Gönczi M, Nagy N, Végh Á. A réskapcsolatok szerepe a prekondicionálás késői 
antiaritmiás hatásában. Magyar Kardiológus Társaság Kongresszusa, Balatonfüred, 2009. 
Cardiologia Hungarica 2009; 39:A43. 
 
 3 
4. Gönczi M, Kiss A, Végh Á. A nátrium-nitrit (NaNO2) védelmet nyújt az 
iszkémia/reperfúzió során megjelenő kamrai aritmiákkal szemben a réskapcsolatok 
befolyásolása által Magyar Kardiológus Társaság Kongresszusa, Balatonfüred, 2010. 
Cardiologia Hungarica 2010; 40:38 
 
5. Gönczi M, Kiss A, Végh Á. A nátrium-nitrit (NaNO2) védelmet nyújt az 
iszkémia/reperfúzió során megjelenő kamrai aritmiákkal szemben a réskapcsolatok 
befolyásolása által Magyar Élettani Társaság LXXIV. Vándorgyűlése 2010 Abstract book: 
97:E5. 
Abstracts for poster presentation 
 
1. Gönczi M, Papp R, Kovács M, Seprényi Gy, Végh Á. Molecular evidence for the role of 
gap junctions in the antiarrhythmic effect of preconditioning 19th World Congress of the 
International Society for Heart Research (ISHR), Bologna, 2007.  
J Mol Cell Cardiol 2007 42(1): S174. 
 
2. Gönczi M, Nagy N, Végh Á. A réskapcsolatok szerepe a prekondicionálás késői 
antiaritmiás hatásában Magyar Élettani Társaság LXXIII. Vándorgyűlése, Budapest 2009. 
Abstract Book: C/31. 
 
3. Gönczi M, Kiss A, Végh Á. The antiarrhythmic protection resulting from sodium nitrite 
(NaNO2) administration involves modulation of gap junctions. XX. World Congress of the 
International Society for Heart Research (ISHR), Kyoto, 2010  
J Mol Cell Cardiol 2010 48(5): S102 
 
4. Gönczi M, Kiss A, Végh Á. Is the modulation of gap junctions involved in the protection 
against ischaemia and reperfusion-induced ventricular arrhythmias by sodium nitrite? VI. 
International Symposium on Myocardial Cytoprotection, Pécs, 2010.  
 
5. Gönczi M., Kovács M., Seprényi Gy., Végh Á. Altered gap junction expression contributes 
to the delayed antiarrhythmic protection induced by rapid cardiac pacing in the canine 
heart XXX. European Section Meeting of the International Society for Heart Research 
(ISHR), Haifa, 2011 Abstract book: P(A)27. 
 4 
 
6. Gönczi M. Kovács M, Seprényi Gy, Végh Á. Role of gap junctions in cardiac pacing-
induced delayed antiarrthythmic protection 75th Anniversary of Albert Szent-Györgyi’s 
Nobel Prize Award, Szeged, 2012. Abstract book: 118: P-C9. 
 
7. Gönczi M, Kovács M, Seprényi Gy, Végh Á. Role of gap junctions in the pacing-induced 
delayed antiarrthythmic protection Conference and Advanced Research Workshop Sudden 
Cardiac Death and Cardioprotection, Timisoara, 2012. Abstract book: 76: P6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
TABLE OF CONTENTS 
 
LIST OF PUBLICATIONS ................................................................................................... 2 
TABLE OF CONTENTS ....................................................................................................... 5 
LIST OF ABBREVIATIONS ................................................................................................ 7 
SUMMARY ............................................................................................................................. 8 
1. INTRODUCTION .............................................................................................................. 10 
1.1 Temporal distribution and mechanisms of acute ischaemia-induced  
ventricular arrhythmias ..................................................................................................... 10 
1.2 Structure and regulation of gap junctions and their role in impulse  
propagation and arrhythmogenesis ................................................................................... 11 
1.3 The cardioprotective effect of preconditioning and the role of Cx43 and  
gap junction channels in the protection ............................................................................. 13 
1.4 Regulatory role of nitric oxide on gap junction channels .................................................. 14 
1.5 Delayed preconditioning and modulation of gap junctions by cardiac pacing .................. 15 
2. AIMS OF THE STUDY ..................................................................................................... 16 
3. MATERIALS AND METHODS ....................................................................................... 17 
3.1 Experimental animals and ethical concerns ....................................................................... 17 
3.2 Surgical preparations .......................................................................................................... 17 
3.3 Measurement of ischaemia severity ................................................................................... 18 
3.4 Measurement of gap junctional electrical coupling ........................................................... 18 
3.5 Assessment of ventricular arrhythmias .............................................................................. 19 
3.6 Assessment of gap junctional metabolic coupling ............................................................. 19 
3.7 Immunoblot analysis .......................................................................................................... 19 
3.8 Immunofluorescence analysis ............................................................................................ 20 
3.9 Gene expression analysis with RT-PCR ............................................................................ 21 
3.10 Experimental protocols .................................................................................................... 21 
3.10.1 Evaluation of the effect of sodium nitroprusside on gap junction function  
during coronary artery occlusion .................................................................................. 21 
3.10.2 Evaluation of the role of gap junctions in the delayed antiarrhythmic  
protection induced by cardiac pacing ........................................................................... 22 
3.11 Statistical analysis ............................................................................................................ 23 
4. RESULTS ............................................................................................................................ 24 
4.1 Evaluation of the effect of sodium nitroprusside on gap junction function  
during coronary artery occlusion .................................................................................. 24 
4.1.1 Haemodynamic changes during SNP infusion and the subsequent coronary  
artery occlusion ............................................................................................................... 24 
4.1.2 The severity of ischaemia during coronary artery occlusion .......................................... 24 
4.1.3 The severity of ventricular arrhythmias during coronary artery occlusion ..................... 24 
4.1.4 The distribution of ventricular premature beats and changes in  
myocardial electrical coupling during coronary artery occlusion .................................. 27 
4.1.5 Changes in gap junction permeability ............................................................................. 27 
4.1.6 Changes in the phosphorylation status of Cx43 .............................................................. 27 
4.2 Evaluation of the role of gap junctions in the delayed antiarrhythmic  
 protection induced by cardiac pacing ............................................................................... 30 
4.2.1 Haemodynamic changes during a 25 min LAD occlusion .............................................. 30 
4.2.2 Chages in epicardial ST-segment and TAT during a 25 min occlusion 
 of the LAD ..................................................................................................................... 30 
 
 6 
4.2.3 The severity of ventricular arrhythmias during a 25 min occlusion  
and reperfusion of the LAD ............................................................................................ 31 
4.2.4 Distribution of VPBs in relation to changes in myocardial electrical  
impedance during LAD occlusion .................................................................................. 31 
4.2.5. Changes in myocardial Cx43 expression after rapid cardiac pacing ............................. 32 
4.2.6. Changes in Cx43 expression during LAD occlusion 24hrs after  
cardiac pacing ................................................................................................................. 33 
4.2.7. Changes in the phosphorylation status of Cx43 and gap junction  
 metabolic coupling ......................................................................................................... 35 
4.2.8. Arrhythmia and ischaemia severity during LAD occlusion 12 hours after  
 cardiac pacing ................................................................................................................ 35 
5. DISCUSSION ..................................................................................................................... 38 
5.1 New findings ...................................................................................................................... 38 
5.2. The effect of sodium nitroprusside on gap junction function during  
myocardial ischaemia ........................................................................................................ 38 
5.3. The role of gap junctions in the delayed phase of preconditioning induced by 
 rapid cardiac pacing ......................................................................................................... 41 
6. REFERENCES ................................................................................................................... 45 
7. ACKNOWLEDGEMENT ................................................................................................. 56 
8. ANNEX ................................................................................................................................ 57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7 
LIST OF ABBREVIATIONS 
 
Cx43  Connexin 43 
DABP  Diastolic arterial blood pressure 
FITC  Fluorescein isothiocyanate 
GJ  Gap junction 
HR  Heart Rate 
LAD  Left anterior descending coronary artery 
LCX  Left circumflex coronary artery 
LVEDP Left ventricular end-diastolic pressure 
LVSP  Left ventricular systolic pressure 
LY  Lucifer Yellow 
MABP Mean arterial blood pressure 
NO  Nitric oxide 
NOS  Nitric oxide synthase 
OTC  Optimal cutting temperature 
PC  Preconditioning 
PVDF  Polyvynildene-fluoride 
SABP  Systolic arterial blood pressure 
SDS  Sodium dodecyl-sulphate 
SNP  Sodium nitroprusside 
TAT  Total activation time 
TD  TRITC conjugated dextran 
TRITC Tetramethyl-rhodamine isothiocyanate 
VF  Ventricular fibrillation 
VPB  Ventricular premature beats 
VT  Ventricular tachycardia 
WGA  Wheat germ agglutinin 
 
 
 
 
 
 8 
SUMMARY 
 
It is well-established that gap junction channels contribute to arrhythmia generation 
during myocardial ischaemia and they play an important role in the early antiarrthymic effect 
of ischaemic preconditioning (PC). There is also evidence that nitric oxide (NO) is a key 
mediator of the PC-induced protection and that the administration of NO donors mimics this 
antiarrhythmic protection. Since NO may modulate gap junction function in non-cardiac 
tissues first we aimed to investigate, whether in an anaesthetised canine model the 
antiarrhythmic effect is due to the modification of cardiac gap junctions by NO. 
  It is also well-described that the protection of PC occurs immediately after the PC 
stimulus and several hours later, in a delayed phase as well. It is also known that the 
protective state could be induced by stimuli other that brief periods of ischaemia, e.g. rapid 
cardiac pacing or heavy physical exercise. Since cardiac pacing has been found to influence 
gap junction function and the expression of Cx43, secondly we aimed to examine the role of 
gap junctions in the delayed phase of the antiarrhythmic protection induced by rapid right 
ventricular pacing  
In order to examine the regulatory role of NO on cardiac gap junctions in 
anaesthetised dogs we administered the NO donor sodium nitroprusside (SNP) in an 
intracoronary infusion in a dose of 0.2μg·kg-1·min-1prior to and during the occlusion of the 
left anterior descending coronary artery (LAD). We evaluated the severity of ventricular 
arrhythmias, changes in myocardial tissue impedance, gap junction permeability as well as the 
phosphorylation status of Cx43. We showed that compared to the controls, the administration 
of SNP markedly reduced the severity of ischaemia and of ventricular arrhythmias and 
prevented the ischaemia-induced gap junctional electrical and metabolic uncoupling and 
dephosphorylation of Cx43. 
Thus we concluded that the antiarrhythmic protection of SNP infusion may, at least in 
part, be due to the modification of gap junctions by NO. 
In the studies aimed to examine the role of gap junctions in the delayed antiarrhythmic 
effect we paced dogs at a frequency of 240beat/min for 4x5min and then subjected them to 
coronary artery occlusion 24h later. Compared to the non-paced controls, pacing significantly 
reduced ventricular arrhythmias and attenuated tissue impedance changes during occlusion,. 
Pacing also prevented the ischaemia and reperfusion-induced structural impairment of the 
intercalated discs and preserved gap junction permeability and the phosphorylation of Cx43. 
We also observed time-dependent changes in Cx43 mRNA and protein expression in response 
 9 
to cardiac pacing, with a significant reduction in Cx43 protein expression 12h after cardiac 
pacing. This reduced Cx43 protein content was accompanied by increased susceptibility to 
arrhythmias and more marked impedance changes if the LAD was occluded at this time point. 
We conclude that cardiac pacing results in time-dependent changes in Cx43 
expression, which may be related to the altered gap junction function and may influence 
arrhythmia generation during ischaemia.  
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1. INTRODUCTION 
Myocardial ischaemia - caused by severe stenosis or complete occlusion of a coronary 
artery – often leads to the generation of severe ventricular tachyarrhythmias and ultimately to 
sudden cardiac death. During the past few decades, despite the development of the facilities in 
interventional cardiology and pharmacological treatments, sudden cardiac death still remains 
one of the leading factors contributing to cardiovascular mortality in the modern world. 
Therefore, better understanding of the mechanisms underlying these acute ischaemia and 
reperfusion-induced life threatening arrhythmias would promote experimental and clinical 
cardiologists to find and develop novel therapeutic strategies. 
1.1 Temporal distribution and mechanisms of acute ischaemia-induced ventricular 
arrhythmias 
The sudden occlusion of a major coronary artery acutely induces the generation of severe 
ventricular arrhythmias, occurring in a characteristic biphasic distribution [1].  The first phase 
of these arrhythmias - termed as phase Ia – generally lasts from the 2nd to the 10th minute of 
ischaemia. The proposed mechanisms of these phase Ia arrhythmias implicate immediate 
reduction of oxygen and energy nutrients within the affected myocardial area, prompting the 
myocytes to switch from aerobic to anaerobic metabolism [2]. As a result of this, ATP stores 
are quickly depleted and the accumulation of lactate in the cytosol causes further glycolytic 
enzyme inhibition and intracellular pH drop [3]. These fast metabolic events directly affect 
ion pump functions and create ionic imbalance across the cell membrane due to Na+/K+ pump 
dysfunction [4], opening of the sarcolemmal KATP channels [5], extracellular pH reduction [3] 
and Na+ channel inactivation [6]. Furthermore, as a consequence of altered function of 
Na+/Ca2+ exchanger, intracellular Ca2+ overload occurs, which is a source of triggered activity 
[7]. These changes are the most prominent in the central zone of the ischaemic area and lead 
to dramatic changes in action potential morphology and duration [7] as well as impulse 
generation and conduction [8]. Within those areas most affected by ischaemia, even 
conduction block may develop. In addition, a high level of spatial inhomogeneity in 
excitability, conduction velocity and tissue refractoriness occurs within the border, the area 
between the normal and ischaemic regions [9] creating the substrate for re-entry arrhythmias. 
This is considered to be a major mechanism underlying phase Ia arrhythmias [7, 10]. 
The first phase is generally followed by a relatively arrhythmia free interval [1Kaplinsky 
1979] or a so-called “compensatory phase”, during which ionic changes become balanced and 
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impulse conduction returns near to normal state for a short period of time [11]. Although the 
mechanism of this arrhythmia free interval is not fully understood, one of the  explanations 
likely be that the release of catecholamines [11] possibly counteracts the acidification and K+ 
efflux [12], and enhances ion pump functions e.g. Na+/K+ pump [13] and normalise impulse 
conduction. It is also likely that endogenous protective substances [14, 15] are released soon 
after the occlusion such as bradykinin [16] and nitric oxide [17], by their favourable 
haemodynamic effects may transiently improve myocardial function during this period. 
However, if ischaemia is further maintained, these compensatory processes are 
attenuated or even exhausted, resulting in further deterioration of myocardial function and the 
appearance of the phase Ib arrhythmias [1]. This phase generally occurs between the 15th and 
the 30th min of ischaemia and often terminates in ventricular fibrillation [18, 19]. Although 
processes underlying the generation of phase Ib arrhythmias are less well understood than that 
of the phase Ia, it is proposed that uncoupling of gap junctions play a pivotal role. This is 
supported by the finding that by this time of ischaemia, the accumulation of catecholamines 
[11, 20 21] the subsequent intracellular Ca2+ overload [22] and the drop of intracellular pH [3] 
create a milieu which facilitates the uncoupling of gap junctions and an increases cellular 
resistance [23, 8] resulting in non-uniform changes in impulse conduction. Coronel et al [24] 
demonstrated that increased wall stretch due to elevated ventricular filling pressure, as well as 
a second rise in extracellular K+ [18], the latter by further increasing spatial heterogeneity, are 
also important contributory factors to the development of phase Ib arrhythmias.  
1.2 Structure and regulation of gap junctions and their role in impulse propagation and 
arrhythmogenesis 
Gap junctions are intercellular channels creating a “cytoplasmic bridge” between 
neighbouring cells. These channels facilitate metabolic and electrical communication among 
cells as they are permeable to molecules of molecular weight less than 1kDa, such as ions and 
second messengers [25, 26]. Gap junctions are formed by connexin protein subunits. Six 
connexins build up a connexon or a hemichannel, and two connexons of adjacent cells form a 
gap junction. In the myocardium, connexin formed intercellular channels aggregate at the 
longitudinal end-to-end connections of the myocytes in the intercalated discs. This cellular 
distribution of gap junction channels creates anisotropy, meaning that cardiac impulse is 
conducted preferably in longitudinal direction instead of transversal to myofibre orientation. 
In the ventricular myocardium the primary isoform is connexin 43 (Cx43) [27]. Connexin 43 
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has a rapid turnover of 1.5hrs, indicating that the total number of available channels can be 
regulated rapidly by affecting Cx43 expression [28, 29]. Furthermore, open probability of the 
channels can be regulated by the phosphorylation of Cx43 as a result of activation of various 
kinase pathways [30, 31]. There is evidence that under certain pathological conditions, such 
as heart failure [32, 33, 34] or myocardial infarction [35, 36], the expression of Cx43 is 
reduced and it is translocated from the intercalated discs to the lateral membrane [37]. These 
changes may contribute to impaired conduction and arrhythmogenesis under these 
pathological conditions.  
McCallister et al [38] were the first to propose that gap junctions uncouple during 
ischaemia. The metabolic alterations i.e. low ATP [39] acidified intracellular pH [40, 41], 
Ca2+ overload [40] and the accumulation of amphiphylic metabolites [42], as well as 
dephosphorylation of Cx43 [43], together with an excessive release of catecholamines [44] 
facilitate the closure of gap junctions and trigger ventricular arrhythmias. In a seminal paper, 
Kléber et al [45] demonstrated that in rabbit papillary muscle subjected to ischaemia, tissue 
resistivity increased in a biphasic manner. The first rise occurred immediately after the onset 
of ischaemia and was associated with cell swelling and tissue edema. A second rise in 
resistivity occurred at about the 15th minute of ischaemia and this was thought to be resulted 
from gap junctional uncoupling [45]. This finding was confirmed later in in vivo experiments 
by showing that in the porcine heart the second steep rise in tissue resistivity due the 
uncoupling of gap junctions was associated with the occurrence of severe ventricular 
arrhyhtmias and a high incidence of ventricular fibrillation [18]. Besides, it also turned out 
that the level and the rate of uncoupling are also important factors for arrhythmia generation. 
There is evidence that ventricular fibrillation most likely occurs, under conditions of a 
“moderate uncoupling” of gap junctions [19, 46] or when uncoupling speeds up. In contrast, a 
more advanced uncoupling attenuates the occurrence of arrhythmias, since the substrate for 
them disappears [8]. 
1.3 The cardioprotective effect of preconditioning and the role of Cx43 and gap junction 
channels in the protection 
 In 1986 Murry et al [47] described a new cardioprotective phenomenon termed as 
ischaemic preconditioning during which repeated sublethal ischaemic episodes provide 
protection against the otherwise lethal consequences of a more prolonged ischaemic insult. 
Since then it has become obvious that preconditioning provides protection not only against 
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ischaemia and reperfusion-induced cell death as well as tissue necrosis, but against ischaemia 
and reperfusion-induced severe ventricular arrhythmias [48] as well as contractile dysfunction 
[49]. It has also been well-established that the protective effect of PC occurs in two distinct 
phases: the early phase is apparent immediately after the stimulus but the protection is short 
lived; it persists only for 1-2 hours. However, the protection re-occurs 20-24 hours later and is 
called the delayed phase [50] or “second window” of the protection [51]. Since the first 
description of this phenomenon many laboratories have dealt with the exploration of the 
mechanisms underlying the PC-induced adaptive phenomenon. It has now become generally 
accepted that a number of endogenous protective substances are released from the 
myocardium during the PC stimulus [14, 52], e.g. adenosine [53], bradykinin [16], ROS [54, 
55], prostanoids [55] and nitric oxide (NO) [17]. These mediators by acting on different 
receptors may stimulate various signalling pathways thus ultimately leading to 
cardioprotection [56].  
More recent evidence suggest Cx43 and gap junctions as one of the major targets in this 
adaptive phenomenon. For example it was demonstrated that in Cx43 heterozygous mice, 
protection could not be induced by PC [57]. Furthermore, in Langendorff-perfused rat hearts 
ischaemic PC delayed the onset of cellular uncoupling, and reduced the ischaemia-induced 
dephosphorylation of Cx43, as well as the translocation of Cx43 from intercalated discs to 
other cellular compartments [58]. Similarly, Boengler et al reported that ischaemic 
preconditioning caused the translocation of Cx43 from the sarcolemma into the inner 
mitochondrial membrane [59], where it is supposed to modulate the mitoKATP channel 
function [60]. The mitochondria are considered as one of the major end-effectors of PC-
induced cardioprotection [61]. There is also evidence that pharmacological closure of gap 
junctions in an in vitro model by heptanol mimicked PC’s protection [62], however when 
heptanol was administered during the PC stimulus abrogated the PC-induced infarct limiting 
effect [63]. The first in vivo evidence came from a study of Cinca et al [64] who demonstrated 
in anaesthetised pigs that ischaemic PC delayed the uncoupling of gap junctions as well as the 
occurrence of ventricular arrhythmias without substantially reducing the number and severity 
of arrhythmias. In our own experiments in anaesthetized dogs we have found that ischaemic 
PC not only delayed but indeed markedly reduced the incidence and severity of ventricular 
arrhythmias during coronary artery occlusion and this effect was associated with a reduced 
uncoupling of gap junctions [65]. We have also demonstrated that the administration a 
selective gap junction uncoupler carbenoxolone prior to ischaemia resulted in a PC-like 
antiarrhythmic protection [65], however, when carbenoxolone was given prior to and during 
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the PC procedure, it abolished the protection [65]. Taken together, there seems to be no doubt 
that gap junction channels plays an important role in arrhythmia generation and also in the 
antiarrhythmic protection afforded by PC. However, the exact mechanisms by which PC 
modulate these channels remains to be elucidated.  
1.4 Regulatory role of nitric oxide on gap junction channels 
 As mentioned above, there are a number of mediators, which are released in response 
to the preconditioning stimulus, among which NO has paramount importance. The first piece 
of evidence that NO participate in the antiarrhythmic effect of preconditioning came from 
those studies, which demonstrated that L-NAME, an inhibitor of the L-arginine-NO pathway, 
given either prior to preconditioning or just before the coronary artery occlusion, attenuated 
the protection against arrhythmias [17]. The second piece of evidence that NO most likely 
plays a role in this antiarrhythmic protection resulted from those studies which showed that 
the administration of NO donors, e.g. nicorandil [66] and isosorbide-2-mononitrate [67] exerts 
a preconditioning-like antiarrhythmic effect. Similarly, the intracoronary infusion of SNAP 
was able to reduce ischaemia-reperfusion injury in anaesthetized pigs [68]. 
 A growing body of evidence shows that NO, among its several other actions, may 
modulate the expression of different connexin isoforms and the gating properties of gap 
junction channels. However, the majority of these results are mainly derived from in vitro 
studies in non-myocardial tissue. For example, Bolanos and Medina described that in 
astrocytes the induction of NOS or the administration of a NO donor reduced the permeability 
of gap junctions [69]. Also, in rat myometrial cells, the NO donor SNAP decreased the 
expression of Cx43 [70]. In an in vivo rat model, iNOS induction following myocardial 
infarction was shown to be responsible for the down regulation of Cx43 expression [35]. On 
the other hand, studies on mesangial cells revealed that NO has a positive regulatory effect on 
connexin expression and gap junction permeability [71]. Furthermore, NO increased de novo 
formation of Cx40 formed gap junctions in endothelial cells [72]. One of the proposed 
mechanisms through which NO is able to modulate gap junctions is the activation of protein 
kinase G, via the soluble guanylate cyclase – cGMP pathway [73]. This pathway is also 
involved in the antiarrhythmic effect of preconditioning [74] and of NO donors [75]. 
However, as to whether NO is able to modulate gap junction channels in cardiac myocytes 
and whether the antiarrhythmic effect of NO donors can be associated with the modulation of 
gap junction function, has still not been examined. 
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1.5 Delayed preconditioning and modulation of gap junctions by cardiac pacing 
 Preconditioning induces not only an early, but also a delayed phase of protection [49]. 
The mechanisms responsible for the induction and development of the delayed phase, differs 
in some aspects from those of the early phase. Whereas the early phase is primarily due to the 
release of endogenous substances [52], and the subsequent activation of their respective signal 
transduction cascades, the development of the delayed phase is attributed to gene and protein 
expression changes via activation of the early signalling events [76]. These proposed changes 
involve the activation of transcription factor NF-κ-B [77], the NO induced iNOS activation 
[78, 79], the upregulation of cyclooxygenase-2 [80], the induction of antioxidant enzymes 
[52] and heat shock proteins [81], etc.  
It was an important recognition in the preconditioning research that both an early and 
a delayed protection can be induced by stimuli other than short ischaemic events. In this 
regard, high frequency right ventricular pacing [82] and heavy physical exercise [83] have 
been shown to serve as preconditioning stimuli. Moreover, of clinical importance is the 
finding that by repeating the stimulus, when the protection from the previous stimuli has 
already waned [84], the protection can be extended over a longer period [85].  
A number of evidence supports the concept that cardiac pacing is able to modify gap 
junction function and expression. For example, Kontogeorgis et al [86] showed that pacing of 
mice hearts for 6 hours reduced endocardial Cx43 level and the redistribution of gap 
junctions. Similarly, Matsushita et al [87] demonstrated that cardiac pacing for 3 hours caused 
dephosphorylation of Cx43 at the vicinity of the pacing site. Furthermore, long-term cardiac 
pacing (more than 3 weeks) in order to induce heart failure, decreased Cx43 expression [88], 
increased the level of dephosphorylated Cx43 in the intercalated discs [89] and altered cellular 
distribution of Cx43 [89, 90]. It is interesting to note, that whereas long-term overdrive 
cardiac pacing induces maladaptive responses, like remodelling of cellular architecture, and 
contributes to the development of heart failure and arrhythmogenesis, the same stimulus when 
applied for short, intermittent periods, induces both early and delayed adaptive processes [82].  
Despite the extensive research, whether gap junctions play a role in this pacing-induced 
delayed protection has not yet been examined. 
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2. AIMS OF THE STUDY 
 The purpose of this thesis is to answer the following questions, raised in two separate 
studies according to the enclosed publications: 
 
a) There is abundant evidence that NO plays an important trigger and mediator role in 
the antiarrhythmic effect of preconditioning and that the administration of NO donors 
mimic the preconditioning-induced protection. In the first series of experiments we 
have attempted to investigate whether this antiarrhythmic effect, at least in part, can be 
attributed to the modulation of gap junction function by NO. 
For this purpose in anaesthetised open-chest dogs sodium nitroprusside (SNP) was 
administered locally into a side branch of the left anterior descending coronary artery 
(LAD) in a dose of 0.2μg·kg-1·min-1. The infusion was started 20 minutes prior to and 
maintained over a 60 minute occlusion period. 
 
b) The role of gap junctions in the early antiarrhythmic effect of preconditioning has 
already well-described, but as to whether they play a role in the delayed phase of the 
protection is still not elucidated. Thus we aimed to investigate whether gap junctions 
participate in the delayed antiarrhythmic of preconditioning induced by rapid right 
ventricular pacing. We also examined the effect of cardiac pacing on gene- and protein 
expression, as well as on the cellular distribution of the gap junction forming protein 
Cx43, at different time points after rapid right ventricular pacing. Since in this 
particular study we observed a significant reduction in the expression of Cx43 12 
hours after cardiac pacing, we designed further studies in which the severity of 
arrhythmias was examined during a 25 min occlusion of the LAD 12 h after cardiac 
pacing. 
 
 
 
 
 
 
 
 
 17 
3. MATERIALS AND METHODS 
 
3.1. Experimental animals and ethical concerns 
All experiments were performed in adult mongrel dogs of either sex with a mean body 
weight of 20 ± 2 kg. The origin and upkeep of the animals were in accord with the Hungarian 
Law (XXVIII, chapter IV, paragraph 31) regarding large experimental animals, which 
confirms with the Guide for the Care and Use of Laboratory Animals published by the US 
National Institute of Health (NIH Publication No. 85-23, revised in 1996). 
3.2. Surgical preparations 
Animals were anaesthetised with pentobarbital (Euthanyl®, 0.5mg · kg-1, Bimeda-
MTC Animal Health Inc.). The right femoral vein was prepared and cannulated for the 
administration of a mixture of α-chloralose and urethane (60 and 200 mg · kg-1 respectively, 
Sigma, St Louis, MO, USA). Further doses of anaesthetic were administered, when it was 
necessary, to maintain anaesthesia. The right femoral artery and the left arteria carotis 
communis were prepared and catheterised in order to measure arterial (systolic: SABP, 
diastolic: DABP, and mean: MABP) and left ventricular blood pressures (systolic: LVSP, 
end-diastolic: LVEDP) respectively. The catheters were connected through Statham 
transducers (Statham P23XL) to a PLUGSYS haemodynamic apparatus (Hugo Sachs 
Electronics, Germany) and signals were recorded on a Graphtec Thermal Array Recorder 
(Hugo Sachs Electronics, Germany). Arterial blood gases and pH were frequently monitored 
(Radiometer ABL 505, Denmark) and ventilation (Harvard Apparatus, Natick, MA, USA) 
was adjusted to maintain these values within the physiological limits.  
After thoracotomy the left anterior descending coronary artery (LAD) was prepared 
for occlusion distal to the first main diagonal branch. This site of occlusion usually results in 
approximately 35% area at risk, which was verified after the experiments by the infusion of 
methylene blue into the LAD at the occlusion site as described previously [82]. Coronary 
blood flows were measured on the left circumflex and the left anterior descending branches 
using a 2.0 mm electromagnetic flowmeter (Statham SP2202) and an ultrasonic Doppler 
flowmeter (Triton Technologies, USA) respectively. 
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3.3. Measurement of ischaemia severity 
This was assessed by the measurement of changes in the degree of inhomogeneity of 
electrical activation and in epicardial ST-segment using two methods. In one series of the 
experiments a composite electrode was sutured onto the epicardial surface of the ischaemic 
myocardial region. This electrode gives a summarised R-wave of 24 bipolar epicardial points. 
In the adequately perfused myocardium, all sites under the electrode are activated 
simultaneously, resulting in a single large spike. However, during occlusion, fractionation and 
widening of this summarized R-wave occurs, indicating that adjacent fibers are not 
simultaneously activated. The inhomogeneity of electrical activation measured as the greatest 
delay in activation was expressed in ms. Additional two unipolar electrodes served for 
measuring changes in epicardial ST-segment, and was expressed in mV. 
In the other series of experiments a mapping electrode was used consisting of 31 
unipolar electrodes (interelectrode distance: 2mm). Signals from this electrode were collected 
together with a chest lead II ECG at a frequency of 1 kHz and stored on a personal computer. 
Data analysis was performed offline. Activation and ST maps were created by means of a 
custom made software. Local activation times at each electrode points were calculated, i.e. the 
time interval between the beginning of ventricular activation on the surface ECG and the 
maximal negative slope [-dV/dtmax] on the unipolar electrogram. Changes in epicardial 
activation were measured as a time delay between the first and the last point activated under 
the electrode and expressed as the total activation time (TAT) in ms. Changes in epicardial 
ST-segment, recorded from 31 unipolar electrode sites were averaged and expressed in mV. 
3.4. Measurement of gap junctional electrical coupling 
Electrical coupling of gap junctions was determined by changes in tissue impedance 
using the four-pinned electrode method [65, 91]. In brief, the electrode was fixed within the 
potentially ischaemic area parallel to myofibre orientation. High frequency subtreshold 
alternating current (10 µA, 8 kHz) was applied between the outer electrode pairs and voltage 
drop was measured between the inner electrode pairs with a lock-in amplifier (SR 830 DSP, 
Stanford Research Systems, CA, USA). Signals were recorded with an acquisition time of 4 
sec on a personal computer with custom made software and analyzed offline. Relative 
changes in tissue resistivity (R; Ohm·cm) and in phase angle shift (°) were calculated and 
plotted at 1 min intervals. Before each experiment, the electrodes were calibrated in saline 
with a known resistivity. 
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3.5. Assessment of ventricular arrhythmias 
The number and incidence of ventricular arrhythmias occurring during LAD occlusion 
was evaluated according to the Lambeth conventions [92] with the modifications outlined 
previously [48]; the total number of ventricular premature beats (VPBs), the number and 
incidence of ventricular tachycardiac episodes (VT) and the incidence of ventricular 
fibrillation (VF) during coronary artery occlusion were calculated. During reperfusion only 
VF was assessed. Dogs that were alive after 5 min of reperfusion were considered as 
survivors (S). 
3.6. Assessment of gap junctional metabolic coupling 
Gap junction permeability was assessed by double dye loading method [93]. 
Euthanasia was performed with an excess dose of anaesthetics at the end of the coronary 
artery occlusion and transmural tissue blocks (approximatetely 0.5x0.5x1.0cm) were excised 
from myocardial areas supplied by the LAD and the left circumflex coronary artery (LCX). 
The samples were immersed into saline containing Lucifer Yellow (LY 1.5mg/ml, Sigma) and 
TRITC-dextran (TD 3.5mg/ml, Sigma) for 15 min. Since LY is a small molecule (~500Da) it 
readily penetrates through gap junctions, whereas TD, which is a large molecule (~ 10kDa), it 
stains only the injured cells on the cutting edge of the tissue. Tissue blocks were then fixed in 
4% paraformaldehyde, dehydrated in 30% sucrose solution containing 0.1% sodium-azide. 
Cryosections (20μm) were made with a Cryostat (Leica) and were mounted on gelatin coated 
slides and covered with PBS-glycerol. Images were taken with an Olympus fluorescent 
microscope (Olympus IX 70) attached to a CCD camera, and were analyzed with Image J 
software (NIH). Metabolic coupling of cells was assessed as the ratio of LY and TD stained 
areas. Permeability within the ischaemic (LAD) area was expressed as the percentage of 
permeability within the non ischaemic area (LCX).  
 
3.7. Immunoblot analysis 
To examine whether cardioprotective interventions cause alterations in Cx43 protein 
content and phosphorylation, Western blot analysis was performed. For this purpose, 
myocardial samples were taken either at the end of the occlusion, or, in the delayed 
experiments, at different time points after cardiac pacing and were stored at -80°C until 
further procession.  Tissue samples were homogenized in ice-cold lysis buffer  consisting of 
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250mM sucrose, 20mM Tris-HCl, 10mM β-mercaptoethanol, 10mM sodium-orthovanadate, 
0.5% protease inhibitor cocktail (Sigma), at pH 7.4. For total protein isolation homogenates 
were centrifuged at 10000g for 15 min, whereas for membrane fraction isolation tissue 
homogenates were centrifuged at 2000g for 10 min. Then the supernatants were collected and 
centrifuged at 100000g for 45 min and the pellet was resuspended in lysis buffer. Protein 
concentrations were determined by the Lowry method. Total (40μg) and membrane protein 
(10-20 μg) samples were separated on 10-12% SDS-polyacrylamide gels and transferred to 
PVDF membranes. After blocking with 5% non-fat milk, membranes were labeled overnight 
at 4°C against Cx43 with a rabbit anti-Cx43 primary antibody (dilution: 1:1000 for total 
protein, 1:2000 for membrane fraction, Zymed) and subsequently HRP-conjugated goat 
secondary antibody (1:8000, Santa Cruz). Blots were developed with ECL Plus Kit on X-ray 
films or scanned with a Typhoon laser scanner (Amersham Biosciences). Band intensities 
were measured using ImageJ software (NIH). For the verification of equal loading, PVDF 
membranes were labelled against GAPDH for total protein content or stained with Coomassie 
Blue for membrane proteins. 
 
3.8. Immunofluorescence analysis 
In order to examine whether the various interventions cause changes in the cellular 
localisation and in the quantity of Cx43 in intercalated discs, immunofluorescence analysis 
was performed. Transmural tissue samples were collected, embedded in OCT compound and 
stored at -80°C. Longitudinal frozen tissue sections (8μm) were cut from the mid-myocardial 
layer and specimens were mounted on gelatine coated slides. Unspecific binding capacity of 
the tissue was blocked with 5% BSA, and the samples were labelled with rabbit anti-Cx43 
primary antibody against Cx43 (1:800, Zymed) overnight at 4°C, then with FITC conjugated 
secondary antibody (1:1500) for 1 h at room temperature, and finally with WGA-conjugated 
Texas Red (1:500, Invitrogen) for 30 min at room temperature. Images were captured with a 
laser scanning confocal microscope (Olympus, FV1000, Olympus) using a 40x magnifying 
objective. Areas of well preserved cardiomyocites were selected for analysis, performed with 
ImageQuant 5.2 (Molecular Dynamics) or Image J (NIH). Relative amount of Cx43 was 
calculated as pixel intensities of intercalated discs with background correction. Samples from 
six individuals from 2 groups were mounted on the same slide at the same time. To compare 
differences between groups, data from each sample were normalized to the sample with the 
highest intensity on the same slide.  
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3.9. Gene expression analysis with RT-PCR 
For the examination of changes in Cx43 gene expression level we performed by RT-
PCR. Total RNA was isolated from tissue samples (25 mg of each heart) using the RNeasy 
Fibrous Tissue Mini Kit (Qiagen, Germany) according to the manufacturer’s instruction. 
Quantitative PCR was performed on an ABI7000 instrument (Applied Biosystems, Carlsbad, 
USA) with gene-specific primers using SybrGreen protocol to monitor gene expression as 
described earlier [94]. From each sample 2 μg of total RNA was reverse transcribed using 
ImPromII Reverse Transcription system (Promega, USA) in the presence of oligo(dT) at 42oC 
for 2h. After this the cDNAs were diluted in 50 μl of water, and 1 μl of the reaction mix was 
used for qPCR. Reactions using SybrGreen protocol were performed with Power SYBR 
Green Master mix (Applied Biosystem, Carlsbad, USA) according to the manufacturer’s 
instructions at a final primer concentration of 250 nM under the following conditions: 10 min 
at 95 oC, 40 cycles of 95 oC for 15s, 60 oC for 25s and 72 oC for 25s. Melting temperature 
analysis was performed after each reaction to check the quality of the reaction.  
Primers were designed using Primer Express 2.0 software package. Relative 
expression ratios were calculated as normalized ratios to HPRT (hypoxanthine guanine 
phosphoribosyltransferase) and to tubulin. Samples were tested for genomic DNA 
contaminations by using non-template controls for each PCR reaction. The final relative gene 
expression changes were calculated as delta-delta Ct values. Genes with expression values 
lower than 0.5 or higher than 1.5 were considered to be down or up-regulated (the values 
correspond to an interval of log2=-1 and log2=0.6). All the PCRs were performed in 
triplicate. 
 
3.10. Experimental protocols 
 
3.10.1. Evaluation of the effect of sodium nitroprusside on gap junction function during 
coronary artery occlusion 
This is illustrated in Fig. 1. Two groups of anaesthetised dogs were used. In the 
control group (C; n=11) saline was infused into a side-branch of the LAD 20 min prior to and 
during the 60 min occlusion of the LAD. In the other group sodium nitroprusside (SNP; n=10) 
was administered in a dose of 0.2μg·kg-1·min-1 20 min before and throughout the occlusion 
period. The syringes containing SNP solution were covered with foil to avoid 
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photodegradation of SNP. The dose of SNP was selected in preliminary experiments using 
increasing doses of SNP in order to find a dose, which caused only minor haemodynamic 
alterations (i.e. less than 5 mmHg reduction in arterial blood pressure).  
 
 
 
 
Figure 1.  Experimental protocol for the evaluation of the cardioprotective effect of sodium 
nitroprusside. Arrows indicate tissue sampling at the end of the 60 min ischaemia.. 
 
3.10.2. Evaluation of the role of gap junctions in the delayed antiarrhythmic protection 
induced by cardiac pacing  
This is illustrated in Fig 2. Under light pentoparbital anaesthesia (0.5mg·kg-1 Euthanyl, 
Bimeda-MTC Animal Health Inc.) a bipolar pacing catheter (Cordat F4, Johnson & Johnson) 
was inserted through the jugular vein into the right ventricle and the hearts were paced four 
times for 5 minutes, with 5 minute intervals, at a rate of 240 beats/min.  Twenty-eight dogs 
were subjected to pacing (P), whereas in another group of animals (n=32) the pacing electrode 
was introduced into the right ventricle but the dogs were not paced. These sham-paced (SP) 
dogs served as controls. From both the paced and control groups 12 dogs were selected and 
divided into four further groups, each containing 3 animals.  In these dogs euthanasia was 
induced by the administration of an intravenous overdose of the anaesthetic at various time 
intervals, i.e. immediately (P-0/SP-0), six (P-6/SP-6), twelve (P-12/SP-12) and twenty-four 
(P-24/SP-24) hours after the pacing or sham-pacing procedures and myocardial tissue samples 
were taken for biochemical analyses (Fig. 2). Dogs that were rendered to occlusion and 
reperfusion were allowed to recover from the surgical interventions and 24 h later were 
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subjected to a 25 min coronary artery occlusion and reperfusion (SP+O; n=20 and P+O; 
n=16) 
 
 
Figure 2. Experimental protocol for the evaluation of the role of gap junctions in the delayed 
phase of preconditioning, induced by rapid cardiac pacing. Arrows indicate time points of 
tissue sampling. P1, P2, P3 and P4 indicate periods of cardiac pacing.  
 
 
3.11. Statistical analysis 
All values are expressed as mean ± s.e.m. Differences between groups were compared 
with Student t-test or Mann Whitney U test, One Way ANOVA or Repeated measures 
ANOVA as appropriate. For analysing arrhythmia events as the number of VPBs, VT 
episodes, and the incidence of VT and VF, Manny-Whitney U test or Fisher exact test was 
used. Differences between groups were considered significant at level p<0.05. 
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4. RESULTS 
 
4.1. Evaluation of the effect of sodium nitroprusside on gap junction function during 
coronary artery occlusion 
4.1.1. Haemodynamic changes during SNP infusion and the subsequent coronary artery 
occlusion 
This is illustrated in Table 1. Intracoronary administration of SNP caused slight but 
statistically significant reductions in arterial blood pressure, left ventricular end-diastolic 
pressure and +dP/dt. These changes were, however, returned to baseline by the beginning of 
the occlusion. LAD occlusion resulted in significant reductions in arterial blood pressure, left 
ventricular systolic pressure and +dP/dt as well as an increase in LVEDP. The heart rate 
remained unchanged. No difference was observed in these haemodynamic paremeters 
between the two groups.  The infusion of SNP did not substantially affect the diastolic blood 
flow and resistance changes, measured in both the LAD and the LCX arteries. The increase in 
compensatory blood flow which occurs on the LCX when the LAD is occluded were also not 
substantially modified by the infusion of SNP. 
 
4.1.2. The severity of ischaemia during coronary artery occlusion 
 This was evaluated by changes in the degree of inhomogeneity of electrical activation 
and in epicardial ST-segment (Fig. 3). In control animals, sudden occlusion of the LAD 
resulted in marked increases in the inhomogeneity of activation and epicardial ST-segment, 
reaching their maximum around the 5th min of the occlusion. These changes remained 
elevated throughout the entire 60 min occlusion period. The intracoronary infusion of SNP 
significantly attenuated the increase of both indices of ischaemia severity. 
 
4.1.3. The severity of ventricular arrhythmias during coronary artery occlusion 
 This is illustrated in Fig 4. In the controls, coronary artery occlusion resulted in high 
number of VPBs (666 ± 202), many separate episodes of VT (8.1±2.3) which occurred in 
55% of the dogs. In those animals which received intracoronary SNP infusion 20 minutes 
prior to and during the occlusion, the ectopic activity (49±18) and the number and incidence 
of VT episodes were markedly suppressed; there were indeed only a few episodes of VT 
(0.2±0.1), which occurred in 2 out of 10 SNP treated dogs (20%). 
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Table 1. Haemodynamic changes following saline and SNP infusion as well as coronary artery occlusion. 
 
 
SABP, systolic arterial blood pressure (mmHg); DABP, diastolic arterial blood pressure (mmHg); MABP, mean arterial blood pressure (mmHg); 
LVSP, left ventricular systolic pressure (mmHg); LVEDP, left ventricular end-diastolic pressure (mmHg); +dP/dtmax (mm Hg·s
-1); -dP/dtmax 
(mmHg·s-1); HR, heart rate (beat·min-1); LAD flow (cm·s-1); LAD resistance (mmHg·cm·s-1); LCX flow (mL·min-1); LCX resistance 
(mmHg·mL·min-1). Values are means ± s.e.m, *p<0.05 compared to baseline values or to pre-occlusion value.
Haemodynamic  
parameters 
Control SNP 
 Baseline 
values 
Saline 
 max. change 
Pre- 
occlusion 
values 
Occlusion  
max. change 
Baseline 
values 
SNP  
max. change 
Pre- 
occlusion  
values 
Occlusion  
max. change  
SABP       146 ± 8 4 ± 2      146 ± 8 -15 ± 2*       149 ± 6 -4 ± 1*          147 ± 6         -10 ± 2* 
DABP       103 ± 6 3 ± 2  96 ± 6 -10 ± 2*       105 ± 6 -4 ± 1*          104 ± 5  -7 ± 2* 
MABP       118 ± 7 3 ± 2      112 ± 6 -10 ± 2*       120 ± 6 -5 ± 1*          119 ± 6  -9 ± 2* 
LVSP       137 ± 9 0 ± 4      128 ± 8 -12 ± 4*       136 ± 7        -3 ± 1          136 ± 7         -13 ± 3* 
LVEDP           9 ± 1 -1 ± 0    8 ± 0    6 ± 1*           9 ± 0        -1 ± 0*      8 ± 0   6 ± 1* 
+dP/dtmax     2719 ± 258 -11 ± 82  3084 ± 263   -416
 ± 177*     2700 ± 290    -192 ± 95*        2673 ± 253  -394 ± 200* 
-dP/dtmax     2894 ± 271 111 ± 153  2630 ± 210 -436
 ± 94*     2904 ± 183    -158 ± 69        2956 ± 207  -695 ± 143* 
              HR       167 ± 6 1 ± 2       158 ± 6  4 ± 2       165 ± 6          3 ± 4          165 ± 5          -1 ± 4 
LAD flow         21 ± 1 1 ± 2         22 ± 1 0         18 ± 0          2 ± 1            19 ± 1              0 
LAD resistance      4.07 ± 0.51 -0.02 ± 0.05      4.08 ± 0.49 0      4.47 ± 0.12    -0.51 ± 0.15         4.18 ± 0.23              0 
LCX flow         70 ± 3 0         70 ± 4         19 ± 6         71 ± 6          3 ± 2            71 ± 6         16 ± 4 
LCX resistance      1.22 ± 0.16 0      1.24 ± 0.13     -0.34 ± 0.10      1.15 ± 0.14    -0.09 ± 0.02         1.14 ± 0.14     -0.27 ± 0.17 
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The intracoronary infusion of SNP in the applied dose did not affect the incidence of 
ventricular fibrillation during coronary artery occlusion. 
 
 
 
 
Figure 3. Changes in the degree of inhomogeneity of electrical activation and in epicardial 
ST-segment during a 60 min coronary artery occlusion in control (black circles) and in SNP 
treated animals (empty circles). Values are means ± s.e.m.,* p<0.05 vs controls. 
 
 
 
 
 
 
Figure 4. Arrhythmia severity during a 60 min LAD occlusion in control (black bars) and 
SNP treated dogs (empty bars).  Values are means ± s.e.m., *p<0.05 vs controls. 
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4.1.4. The distribution of ventricular premature beats and changes in myocardial electrical 
coupling during coronary artery occlusion 
 In the control group, occlusion of the LAD resulted in a high number of VPBs which 
were distributed in two distinct phases; phase Ia arrhythmias occurred soon after the 
commencement of coronary artery occlusion and peaked between 3rd and 8th min of the 
ischaemia. During this period there was a sudden increase in tissue resistivity (Rrel) and a 
decrease in phase angle (φrel). After these immediate changes, ectopic activity started to 
decrease and changes in tissue impedance became slower. However, a second steep rise in 
tissue resistivity and a reduction in phase angle occurred at around the 15th min of ischaemia, 
accompanied by the appearance of phase Ib arrhythmias (Fig. 5.). These arrhythmias lasted 
until about the 30th min of ischaemia. Thereafter ectopic activity faded, but tissue impedance 
changes continued over the rest of the occlusion. 
The intracoronary infusion of SNP alone did not cause any significant change in tissue 
impedance values. In these SNP treated dogs, occlusion of the LAD resulted in less marked 
tissue impedance changes, especially during phase Ib than the controls and ventricular ectopic 
beats were almost completely abolished.  
 
4.1.5. Changes in gap junction permeability  
The metabolic coupling of cells was examined by the measurement of gap junction 
permeability after 60 min ischaemia in controls and in SNP treated dogs. In control samples 
taken from the ischaemic myocardial wall, gap junction permeability reduced to 65±3 % of 
the permeability observed in the non-ischaemic samples (100±7 %). In contrast, in dogs given 
SNP infusion, gap junction permeability was reduced only to 95±5 % of the non-ischaemic 
samples, indicating a preservation of metabolic coupling of cells by SNP. 
 
4.1.6. Changes in the phosphorylation status of Cx43 
 The phosphorylated and dephosphorylated isoforms of Cx43 were determined at the 
end of a 60 min ischaemia in control and in SNP treated dogs. The phospho-dephospho ratio 
of Cx43 is illustrated in Fig 6.b together with representative Western blot images (Fig 6.a).  
Connexin43 occurred in two distinct bands; the 41kDa band represents dephosphorylated 
Cx43 (dP-Cx43) while the 45kDa band indicates phosphorylated Cx43 (P-Cx43) isoform. In 
the non-ischaemic control samples, the P/dP-Cx43 ratio was almost equal (53/47% ± 1%). 
This was shifted towards dephosphorylation by the end of a 60 min coronary artery occusion 
in ischaemic samples, resulting in a 29/71% ± 4% P/dP ratio. In dogs infused with SNP, the 
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P/dP ratio was 58/42% ± 1 % in non-ischaemic samples, and it was 62/38% ± 1% in 
ischaemic samples at the end of the 60 min occlusion, indicating that SNP infusion prevented 
the ischaemia-induced dephoshorylation of Cx43. 
 
 
 
Figure 5. Distribution of VPBs as well as changes in tissue electrical impedance in control 
(black) and SNP treated groups (empty). Values are means ± s.e.m. *p<0.05 vs controls. 
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Figure 6. Ratio of P-Cx43 and dP-Cx43 (expressed as the percentage of the total membrane 
Cx43 content) in ischaemic and non-ischaemic myocardial tissue samples, obtained from 
control and SNP treated dogs. A representative Western blot image is also shown. Values are 
means ± s.e.m. *p<0.05 vs control non-ischaemic, #p<0.05 vs control ischaemic. 
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4.2. Evaluation of the role of gap junctions in the delayed antiarrhythmic protection 
induced by cardiac pacing 
 
4.2.1. Haemodynamic changes during a 25 min LAD occlusion  
 These are summarized in Table 2. There were no significant differences between the 
control and paced dogs in the haemodynamic parameters determined at baseline. In control 
dogs, occlusion of the LAD resulted in significant decreases in arterial blood pressure, 
LVsystolic pressure, positive and negative LVdP/dtmax and increases in LVEDP and heart 
rate. These changes were similar in the paced dogs, except that the increase in LVEDP was 
somewhat less pronounced following coronary artery occlusion. 
 
 
Haemodynamic 
parameters 
SPO PO 
 Baseline 
Post occlusion max 
change 
Baseline 
Post occlusion max 
 change 
SABP 156 ± 5 -11 ± 2* 150 ± 4  -7 ± 4* 
DABP 108 ± 4   -9 ± 1* 101 ± 4                 -7 ± 4 
MABP 123 ± 4   -9 ± 1* 118 ± 4                 -5 ± 4 
LVSP 139 ± 5            -11 ± 1* 134 ± 5                 -4 ± 5 
LVEDP     9 ± 1     4 ± 1*     9 ± 1  2 ± 1 
+dP/dtmax    2937 ± 125          -536 ± 85*   2896 ± 186  -379 ± 193* 
-dP/dtmax  2662 ± 137          -511 ± 119*   2662 ± 153  -386 ± 138* 
HR      159 ± 6     5 ± 1*   149 ± 10   7 ± 1* 
 
Table 2. Haemodynamic changes during a 25 min LAD occlusion in sham-paced (SPO) and 
paced (PO) dogs. Values are means ± s.e.m, *p<0.05 compared to baseline values. 
 
 
4.2.2. Chages in epicardial ST-segment and TAT during a 25 min occlusion of the LAD 
This is illustrated in Figure 7. These indices of ischaemia severity were assessed by 
recording epicardial unipolar ECG signals from 31 distinct epicardial sites. In sham-paced 
controls, occlusion of the LAD resulted in a sudden increase in TAT and similarly in 
epicardial ST-segment, indicating the rapid development of ischaemia following LAD 
occlusion. In contrast, in dogs subjected to cardiac pacing 24h previously, these ischaemia-
induced changes were significantly less pronounced. 
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Figure 7.  Changes in ischaemia severity in SPO (black circles) and PO (empty circles) dogs 
during a 25 min coronary artery occlusion.. Values are means ± s.e.m., *p<0.05 vs SPO. 
 
4.2.3. The severity of ventricular arrhythmias during a 25 min occlusion and reperfusion of 
the LAD 
 This is shown in Fig 8. Compared to the sham-paced controls in which LAD occlusion 
resulted in high number of VPBs (294 ± 78) and many episodes of VT (7.4 ± 2.2) that 
occurred in 60% of animals, in dogs subjected to cardiac pacing 24h previously, the number 
of VPBs (63 ± 25) as well as the number (1.1 ± 0.6) and the incidence (25%) of episodes of 
VT were significantly reduced. Although cardiac pacing did not substantially modify the 
incidence of VF during occlusion, it markedly increased survival from the combined 
ischaemia-reperfusion insult (78% vs 20%).  
 
4.2.4. Distribution of VPBs in relation to changes in myocardial electrical impedance during 
LAD occlusion 
 These are illustrated in Fig 9. In control dogs, immediately after the onset of 
ischaemia, a steep increase in tissue resistivity and a decrease in phase angle occurred, 
accompanied by the appearance of phase Ia arrhythmias. This was followed by a short, 
relatively arrhythmia-free interval, during which myocardial impedance changes were also 
attenuated (Fig 9a). However, at around the 13th min of the ischaemia a second rise in tissue 
resistivity and a decline in phase angle occurred, followed by the occurrence of severe ectopic 
activity. These arrhythmias, as well as the abrupt changes in tissue impedance were 
significantly attenuated especially during phase Ib in dogs subjected to cardiac pacing 24h 
previously (Fig 9b).  
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Figure 8. The total number of VPBs, the number of episodes and the incidence of VT, the 
incidence VF during LAD occlusion, as well as survival after reperfusion in SPO (black bars) 
and in PO (empty bars) dogs. Values are means ± s.e.m. *p<0.05 vs SPO. 
 
 
4.2.5. Changes in myocardial Cx43 expression after rapid cardiac pacing 
 In order to determine whether intermittent periods of cardiac pacing modifies Cx43 
expression in the canine myocardium, we performed immunoblot, immunohistochemical and 
RT-PCR analyses from myocardial samples taken at various time points after cardiac pacing 
over a period of 24h. The results are shown in Fig 10.  Since data obtained from sham-paced 
animals at different time points were almost identical, these were pooled (n=12).  Compared 
to the sham paced controls, in paced dogs there were no significant changes either in total 
(Fig 10a.) or in the Cx43 content of intercalated discs (Fig 10b and d) up to 12h after cardiac 
pacing. However, at this time point both total and membrane Cx43 contents were significantly 
decreased, preceded by a marked down regulation of Cx43 mRNA expression at 6h after 
pacing (Fig 10c). Nevertheless, mRNA expression was already up regulated at 12h and 
subsequently Cx43 protein content as well as mRNA level returned to normal by 24h, 
resulting in no significant differences between SP and P groups prior to the coronary artery 
occlusion. 
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Figure 9. Distribution of VPBs and changes in tissue impedance during a 25 min occlusion 
24 h after sham-pacing (a), pacing (b) as well as when occlusion was performed 12h after 
cardiac pacing (c). Values are means ± s.e.m. *p<0.05 vs SPO. 
 
 
4.2.6. Changes in Cx43 expression during LAD occlusion 24hrs after cardiac pacing 
 These results are illustrated in Fig 11. Compared to the pre-occlusion Cx43 levels (SP 
and P24) occlusion of the LAD resulted in no significant alterations in total or in membrane 
Cx43 protein content in either of the groups (Fig11a and b). Cx43 mRNA level was also 
unchanged after coronary artery occlusion and reperfusion in both groups (Fig 10c). However, 
immunohistochemical images showed that in control dogs subjected only to occlusion or to a 
combined occlusion-reperfusion insult, the end-to-end connections became “blurred” (Fig 11. 
c), indicating a structural impairment of the intercalated discs. This alteration was particularly  
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Figure 10. Time-course changes in Cx43 total protein level (a), mRNA expression (c) and 
Cx43 immunosignal in intercalated discs (b) with representative confocal immunofluorescent 
images d) of end-to-end connections (green) with sarcolemmal staining (red) at different time 
points after cardiac pacing. Arrow heads point to intercalated discs.  Scale bar=50μm. 
Values are means ± s.e.m. *p<0.05 vs SP. 
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marked in samples, which were taken 5 min after reperfusion. In contrast, the structural 
integrity of end-to-end connections was well-preserved in paced dogs, following a 25 min 
ischaemia-reperfusion insult. 
 
4.2.7. Changes in gap junction metabolic coupling and in the phosphorylation status of Cx43  
 These were assessed in samples taken from dogs that underwent a 25 min coronary 
artery occlusion without reperfusion. Gap junction permeability in the controls was 
significantly reduced within the ischaemic area to 68 ± 3 % compared to the non-ischaemic 
value (100±3%). In contrast, in dogs paced 24h previously, gap junction permeability within 
the ischaemic myocardial wall was only slightly reduced (97±5% of the permeability 
measured in non-ischaemic samples) by the end of the 25 min LAD occlusion. 
 The ischaemia-induced changes in the phosphorylation of Cx43 are illustrated in Fig 
12. In control and paced dogs, the P/dP ratio within the non-ischaemic samples was 
64/36±2%.  In control dogs, occlusion of the LAD caused significant dephosphorylation of 
Cx43 resulting in a shift of P/dP ratio to 46/54±4%.  In contrast, in dogs subjected to cardiac 
pacing 24h prior to the occlusion, the P/dP ratio was 61/39 ± 1% and 62/38 ± 1%, within the 
non-ischaemic and the ischaemic region, respectively. These results indicate that pacing 
prevented the ischaemia-induced dephosphorylation of Cx43.  
 
4.2.8. Arrhythmia and ischaemia severity during LAD occlusion 12 hours after cardiac 
pacing 
In order to determine ischaemia and arrhythmia severities at a time point when Cx43 
contents were markedly reduced, other nine dogs were subjected to a 25 min coronary artery 
occlusion and reperfusion 12h after cardiac pacing. In three dogs out of these 9 dogs, 
occlusion of the LAD resulted in only few ectopic beats (50 ± 11) and no VT during the 
occlusion period, and two of these dogs even survived the rapid reperfusion. However, six 
dogs exhibited many VPBs (211 ± 61) and episodes of VT (5.2 ± 2.7) that occurred 
particularly during the later period of the occlusion i.e. between 13 and 25 min. These Ib 
phase arrhythmias were somewhat more marked than those obtained in the controls during the 
same occlusion period. Furthermore, two of these 6 dogs experienced VF during occlusion 
and none of them survived reperfusion. Similar to the sham paced controls, changes in tissue 
resistivity and phase angle were more pronounced in dogs paced 12h before occlusion 
compared to those which had been paced 24h prior to occlusion (Figure 9). Whereas there 
were no significant differences in epicardial ST segment changes between the controls and 
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dogs that had been paced 12h previously (at 5 min of the occlusion in dogs paced 12h before: 
17 ± 1mV vs. 20 ± 2 mV, and at 20 min of the occlusion: 15 ± 3 vs. 16 ± 1 mV), the increases 
in TAT were substantially higher in these paced dogs (120 ± 17 and 113 ± 9 ms) than in the 
non-paced controls (83 ± 9 and 89 ± 11 ms). 
 
 
 
 
 
Figure 11. Total (a) and membrane Cx43 content (b) in control and paced dogs after a 25 
min coronary artery occlusion and reperfusion. c) Confocal images of end-to-end connections 
(green) in ischaemic (LAD) and non-ischaemic (LCX) myocardial sections. Arrow heads 
point to intercalated discs. Scale bar=50μm.  Values are means ± s.e.m. 
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Figure 12.  Changes in the phosphorylated and dephosphorylated isoforms of Cx43 after a 25 
min LAD occlusion in control (SP+O) and paced dogs (P+O). Tissue samples were taken 
from ischaemic (LAD) and non-ischaemic (LCX) myocardial wall regions. Values are means 
± s.e.m. *p<0.0.5 vs SP+O LCX. 
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5. DISCUSSION 
5.1 New findings 
1. We provided evidence that the intracoronary infusion of SNP in a dose of 0.2μg·kg-1·min-1 
markedly reduces the severity of ischaemia and of ventricular arrhythmias during a 60 min 
period of coronary artery occlusion. This protection may result from the ability of SNP to 
release NO. The present results propose that this NO, among its several other effects can 
inhibit uncoupling of gap junctions and preserve gap junction function during ischaemia. This 
effect may certainly play a role in the antiarrhythmic effect of SNP. 
2. We have demonstrated that cardiac pacing results in a time-dependent change in Cx43 
expression, which almost certainly contributes to the altered gap junction function following 
ischaemia and reperfusion, 24 h later. This effect is manifested in reduced uncoupling of gap 
junctions, preserved phosphorylation of Cx43 and gap junction permeability, as well as the 
maintenance of the structural integrity of intercalated discs; all these pacing-induced changes 
at gap junction level may account for the protection against arrhythmias  resulting from 
ischaemia and reperfusion. This assumption is supported by the finding that when Cx43 
content is considerably reduced, more severe gap junctional uncoupling occurs and the 
myocardium becomes more susceptible to arrhythmias. This observation may have a clinical 
relevance, by raising the possibility that there is a critical time-window after a preconditioning 
stimulus, when the heart becomes more vulnerable to arrhythmias in case of an ischaemic 
event. 
 5.2. The effect of sodium nitroprusside on gap junction function during myocardial 
ischaemia 
 In a previous study, we have demonstrated that the marked antiarrhythmic effect of 
ischaemic preconditioning is associated with the preservation of gap junction electrical and 
metabolic coupling and with the prevention of the ischaemia-induced dephosphorylation of 
the main gap junction protein Cx43 during myocardial ischaemia [65]. We have also shown 
that this protective effect of preconditioning is NO-dependent [17], and that drugs which are 
able to donate NO exert similar antiarrhythmic effect to that of preconditioning [67]. 
Although there is increasing evidence coming mainly from non-cardiac tissues [70, 71, 95, 
96] and also from the vasculature [97] that NO is an important regulator of gap junction 
channels and is able to modulate the expression of different connexins, still such an 
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information for the a role of NO in the myocardium is lacking. Thus, we designed studies to 
investigate whether the antiarrthythmic effect of an NO donor can be attributed to the 
modification of gap junction channels by NO. For this purpose, we used the NO donor SNP in 
our anaesthetised dog model of ischaemia and reperfusion. The results confirmed our 
previous findings that drugs, which are able to release NO, protect the myocardium against 
ishaemia and reperfusion-induced ventricular arrhythmias. However, the protective effect of 
SNP was less pronounced than that obtained either with nicorandil [66], or isosorbide-2-
mononitrate [67]. Although SNP almost completely abolished the ectopic activity, it failed to 
reduce the incidence of more severe arrhythmias such as VF. There are conflicting results 
regarding the effect of NO donors on ischaemia-induced arrhythmias. For example, in 
anaesthetised rats [98, 99] different NO donors (nitroglycerine, SNP, SIN-1 and isosorbide-
dinitrate) failed to influence arrhythmia severity, whereas in anaesthetised pigs [100, 101] and 
also in human patients [102, 103] organic nitrates were effective antiarrhythmic agents. The 
reason for these conflicting results can be attributed to the differences in the models used, the 
dose and route of the administration of NO donors, as well as the ability of different donor 
molecules to release NO [104]. However, another explanation might be that in the present 
study the average body weight of the dogs involved was smaller (between 15-25 kg) than in a 
previous study with isosorbide-2-monomitrate [67]. As it has been pointed out body weight 
can be one of the factors, which may determine the susceptibility of the heart to arrhythmias 
[17, 105]. Although the precise mechanism by which NO donors protect against arrhythmias 
is still not fully understood, other beneficial effects, such as anti-platelet aggregatory effect, 
the favourable haemodynamic effects, as well as coronary vasodilatation may also account for 
the antiarrhythmic protection [100, 101]. In our present study, the latter seems unlikely to be 
responsible for the antiarrhythmic protection, since the SNP in the applied dose did not affect 
either baseline coronary blood flow or the compensatory coronary flow (Table 1). 
 The modulation of gap junction function following SNP administration was assessed 
under both in vivo and in vitro conditions by measuring changes in tissue electrical 
impedance, gap junction permeability and Cx43 phosphorylation. We demonstrated that in 
contrast to the controls, SNP administration significantly attenuated the ischaemia-induced 
increase in tissue resistivity without considerably affecting phase angle shift. Although in 
SNP treated animals there was a sudden reduction of phase angle during the first 5 min of 
ischaemia, interestingly, these abrupt changes were not accompanied by an increased ectopic 
activity (Fig 5.). This phenomenon deserves further investigation. Nevertheless, the second 
decline in phase angle which occurred before the appearance of phase 1b arrhythmias in the 
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controls, in the presence of SNP remained almost unchanged. This supports the hypothesis 
that the attenuation of gap junctional uncoupling during this “critical” phase of ischaemia is 
indeed associated with the suppression of arrhythmias [65].  It is well-established that this is 
the period of ischaemia when catecholamines are released [11] and further increase the 
electrical instability of the heart [106]. There is also evidence that NO is able to inhibit 
noradrenaline release from the sympathetic nerve endings [107] and facilitate the release of 
acetylcholine [108, 109]. Both effects may account for the antiarrhythmic effect and the 
improvement of cellular coupling perhaps by the prevention of the iscahemia-induced 
dephosphorylation and degradation of Cx43 [110, 111].  
Although the present study provided the first functional evidence that NO is able to 
modulate myocardial gap junctions, the exact regulatory mechanisms remains to be 
unanswered. Also, we do not know, whether NO directly or indirectly affects gap junctions 
and whether NO opens or closes these intercellular channels in the myocardium. For example, 
NO by reducing intracellular Ca2+ overload – a key signal for gap junctional uncoupling [112] 
- through the phosphorylation of L-type Ca2+ channel via PKG [113] and by the activation of 
SERCA2a [114] may indirectly inhibit the ischaemia-induced gap junctional uncoupling. 
Several, sometimes diverse signalling pathways are proposed to play a role in the regulation 
of gap junctions [30]. We think that one possible way might be the stimulation of sGC-cGMP 
pathway by NO and the subsequent activation of PKG [115], which by phosphorylating Cx43 
is able to modify gap junction function [116]. On the other hand, S-nitrosylation of Cx43 
might also be a possible mode of action by which NO is able to directly affect channel 
function [117, 118]. Apart from these, there may be other possible pathways whereby NO can 
indirectly influence gap junction coupling.  
 In summary, this study provided the first evidence that the antiarrhythmic effect of 
SNP, at least in part, can be attributed to the effect of NO on gap junctions, as their function is 
largely preserved in the presence of SNP during coronary artery occlusion. Besides the 
favourable haemodynamic and anti-ischaemic effects of NO, the activation of more specific 
signalling pathways directed to gap junctions are most likely involved in the antiarrhythmic 
effect of SNP, nevertheless to explore the exact mechanism of this protection warrants further 
investigations. 
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5.3. The role of gap junctions in the delayed phase of preconditioning induced by rapid 
cardiac pacing 
 In a previous study we have demonstrated that repeated, brief periods of rapid cardiac 
pacing through the right ventricle markedly reduces the severity of ventricular arrhythmias 
occurring during a subsequent coronary artery occlusion and reperfusion 24 h later [82]. 
Although the precise mechanism of this protection is still not fully understood, it was 
proposed that the global ischaemic changes - caused by rapid right ventricular pacing - 
induces the release of protective substances [119], via the activation of gene expression [76] 
evoke the delayed protection. In a more recent study we have demonstrated that gap junctions 
play a role in the early antiarrhythmic effect of ischaemic preconditioning [65]. Furthermore 
we showed that NO, which is a key mediator of both the early [17] and the delayed [120, 121] 
protection may also modulate gap junction channels (see the first part of the present thesis) 
thus influencing arrhythmia generation during an acute coronary artery occlusion. There is 
also increasing evidence that cardic pacing – depending on the duration of the stimulus – can 
induce adaptive (short-term pacing) and maladaptive (long-term pacing) processes by 
influencing the expression, cellular localization and phosphorylation of the main structural 
protein of gap junctions, Cx43 [86-90].  
 On the basis of these previous results we designed studies to examine whether gap 
junctions also play a role in the delayed antiarrhythmic effect afforded by cardiac. This was 
examined in our anaesthetised canine model using various in vivo and in vitro measurements. 
The results of the in vivo experiments demonstrated that the marked reduction in arrhythmia 
severity and mortality during a 25 min LAD occlusion 24 h after cardiac pacing was 
associated with attenuated electrical uncoupling of gap junctions; the changes in tissue 
impedance were significantly less pronounced especially during phase Ib in the paced dogs 
than in the sham-paced controls. This preserved cell-to-cell electrical coupling in the paced 
group was also reflected by less pronounced increase of TAT indicating better impulse 
conduction within the ischaemic area. This, together with the less marked elevation of 
epicardial ST-segment in paced dogs supports those previous findings that cardiac pacing 
reduces ischaemia severity 24 later [82]. 
 These results have been confirmed by the in vitro measurements, performed in 
myocardial samples taken at the end of the experiments. These showed that rapid cardiac 
pacing 24 h prior to occlusion preserved Cx43 phosphorylation as well as gap junction 
permeability after a 25 min period of occlusion. These findings are in accord with previous 
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results showing that ischaemic preconditioning prevents Cx43 dephosphorylation and 
preserves metabolic coupling of myocytes during myocardial ischaemia when it is performed 
soon after the preconditioning stimulus [58, 65]. More recently, the preservation of Cx43 
phosphorylation and cellular coupling during the delayed phase of the protection have been 
found by the activation of cardiac muscarinic M3 receptors [122]. However, we could not find 
difference in Cx43 phoshporylation between the paced and the control group, when 
reperfusion had been performed. A possible explanation for this might be that Cx43 
dephosphorylation rapidly recovers after a short period of ischaemia (less than 30 min) when 
the myocardium is reperfused [87]. We have also failed to demonstrate substantial changes in 
total and membrane Cx43 protein content after a 25 min ischaemia/reperfusion insult. This 
was in contrast with other studies, which showed a significant decrease in Cx43 protein level 
in the epicardial border zone of dogs after 30 min of ischaemia [123] or even a 20 min 
ischaemia [124]. Nevertheless, other studies suggest that a fairly prolonged period of 
ischaemia is required (i.e. more than 1h) to observe significant Cx43 degradation [125]. In 
this respect, our results are in accordance with those studies, which demonstrated that Cx43 
dephosphorylation may occur, without a net loss of protein level after a 40 min period of 
ischaemia [43]. 
 We have found however, considerable changes during the analysis of Cx43 
immunofluorescence signal of intercalated discs. In control dogs, there were apparent signs of 
structural impairment at the longitudinal cell-to-cell connections both at the end of the 
occlusion period and particularly when the myocardium was reperfused. This faint or dim 
Cx43 signal density in the intercalated discs may indicate ultrastructural changes, such as 
membrane disruption or internalization of Cx43 [43, 124] at the end-to-end connections 
during the ischaemic period. It is also possible that these structural changes resulted from the 
ischaemia-induced altered interactions between Cx43 and other structural proteins, such as c-
Src and ZO-1 [123, 126, 127]. Whatever the explanation for this phenomenon is, it seems that 
cardiac pacing interferes with these processes, since cardiac pacing preserved the structure of 
the intercalated discs both during occlusion, as well as after reperfusion. However, in contrast 
to others, using more prolonged period of cardiac pacing [86, 87], we did not observe any 
sign of Cx43 lateralization at any time point after cardiac pacing. 
 Interestingly, cardiac pacing itself resulted in time-dependent changes in Cx43 mRNA 
and protein expressions. We observed almost a 50% reduction in total Cx43 protein content, 
12 h after pacing and this was preceded 6 h earlier by a significant down regulation of Cx43 
mRNA. A similar effect was observed in an in vivo mice model with 6h of overdrive pacing 
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[86]. It is also interesting to note that in our model, pacing the heart from the right ventricle 
caused global changes affecting the left ventricle as well, where these expression changes in 
Cx43 protein and mRNA were observed. Although we do not know how cardiac pacing 
modifies Cx43 gene and protein expression, it most likely interferes somehow with Cx43 
turnover [86, 124, 128]. A plausible explanation might be that endogenous substances 
released during the pacing stimulus may play a role. One such substance might be NO, which 
is a key mediator of both the early and the delayed antiarrhythmic protection [17, 82, 120, 
121], and as we (see the previous section of the present thesis) and others [36, 70, 71] 
proposed that NO is able to modulate gap junctions. There is evidence that NO, derived from 
iNOS activation, reduces myocardial Cx43 protein expression in anaesthetised rats [129] and 
in mice [36]. Furthermore, pacing the heart from the right ventricle – apart from causing 
transient ischaemia – interferes with normal activation sequence of the ventricles and 
increases wall stretch. This via the activation of the renin-angiotensin aldosterone system can 
lead to the redistribution gap junctions and to a reduction in Cx43 protein level [130]. 
Whatever the mechanism is cardiac pacing results in transient down regulation of Cx43 
mRNA at 6h and protein expression at 12 h after pacing and these changes are definitely 
restored to normal level within another 12 h, when the delayed effect of a preconditioning 
stimulus is usually apparent (Fig 10). 
 In this particular study we have raised the question: if gap junctions through the 
modification of Cx43 are indeed involved in the delayed phase of the protection, then what 
would happen to the arrhythmias, when the expression of Cx43 was markedly reduced (i.e. 
12h after pacing). This was important to know because we had previous evidence that the 
antiarrhythmic protection afforded by cardiac pacing wanes 1 and 6 h after the pacing 
stimulus [82], but in that particular study the severity of arrhythmias has not been examined 
12h after pacing. Therefore we performed a series of experiments in which nine dogs were 
subjected to LAD occlusion and reperfusion 12 h after cardiac pacing and the severity of 
ischaemia and ventricular arrhythmias in relation to tissue impedance changes were assessed. 
Three out of these dogs exhibited only few ectopic beats and two of them survived, but in six 
dogs more severe ischaemic changes occurred compared with the controls. In these 6 dogs 
there were a large number of VPBs, and many episodes of VTs particularly during Ib phase 
and none of them survived the combined ischaemia-reperfusion insult. Tissue impedance 
changes were also more marked in these dogs than in the controls, indicating more severe gap 
junctional uncoupling. Although some studies suggest that almost a 90% reduction of 
myocardial Cx43 protein level is needed to increase the susceptibility of the heart to 
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arrhythmias [131, 132], we suppose that under certain circumstances such as myocardial 
ischaemia, a less marked reduction (around 50%) is already sufficient to promote arrhythmia 
generation. This assumption is supported by the findings which showed that myocardial 
conductivity is unaltered at reduced myocardial Cx43 level under normal conditions [133] but 
it is definitely associated with higher arrhythmia vulnerability in case of an ischaemic event 
[134]. From our findings, it is tempting to conclude that the reason for the increased 
propensity for arrhythmias 12h after pacing was due to the reduction of Cx43 and the 
impairment of electrical cell-to-cell coupling. We think that our results might also have 
clinical importance by pointing out that after a preconditioning-like stimulus, such as cardiac 
pacing or heavy physical exercise [83, 135, 136], there is a critical time interval, when an 
ischaemic condition may result in severe, or even fatal cardiac event. 
 In summary we have demonstrated that cardiac pacing results in time-dependent 
changes in Cx43 gene and protein expression. The reduced Cx43 protein level 12h after the 
pacing stimulus is associated with higher susceptibility for arrhythmias if an ischaemic 
challenge occurs during this period. Cardiac pacing also preserves gap junction function 
during a coronary artery occlusion 24h later by preventing the structural impairment of end-
to-end connections during ischaemia and upon reperfusion, thus reducing the occurrence of 
severe ventricular arrhyhtmias. Our results suggest that gap junction channels are certainly 
play a role in the cardiac pacing induced delayed antiarrhythmic protection. 
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